Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
Reported by The Sydney Morning Herald. We will add other newspapers as they cover it.
How the newspaper covers this story
Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
